NAD+ (nicotinamide adenine dinucleotide) is a core coenzyme for cellular energy metabolism, DNA repair, and epigenetic regulation. NAD+ levels decline significantly with age—dropping to approximately 50% in individuals aged 60 compared to those aged 25. NMN (β-nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most extensively studied NAD+ precursors, yet they differ substantially in pharmacokinetics and bioavailability.
NMN and NR follow different absorption pathways: orally ingested NMN is partially degraded into NR by CD38 enzymes in the gut. NR then enters the bloodstream via intestinal transporters, converts to NMN in the liver, and is finally transformed into NAD+ by NMNAT enzymes. This implies that oral NMN undergoes an indirect "NMN→NR→NMN→NAD+" conversion pathway, which is less efficient than direct supplementation. However, research by Dr. Shin-ichiro Imai's team at Washington University revealed that small intestine epithelial cells express Slc12a8 transporters capable of directly transporting NMN into cells—supporting the feasibility of direct NMN supplementation.
Dosage form significantly impacts bioavailability. Standard oral NMN capsules have a bioavailability of approximately 10-15% due to intestinal CD38 degradation and first-pass metabolism. Liposomal NMN, protected by a phospholipid bilayer, can increase bioavailability to 30-50%. Sublingual NMN bypasses the gut's first-pass effect, entering systemic circulation directly. NR exhibits slightly higher bioavailability than standard oral NMN (approximately 15-25%), though it still faces intestinal degradation. Sublingual and sustained-release NR formulations can further enhance absorption efficiency.
Human Clinical Trial Data Comparison: A study by Keio University in Japan found that daily oral intake of 250 mg NMN for 12 weeks increased blood NAD+ levels by approximately 40%. Meanwhile, a study from the University of Colorado showed that daily oral intake of 1000mg NR over 6 days raised blood NAD+ levels by about 60%. It is important to note that an increase in blood NAD+ levels does not directly equate to an increase in tissue NAD+ levels, as different tissues vary in their efficiency for uptake and utilization of NAD+ precursors.
Dinas Group (Hong Kong) offers a range of NAD+ boosting solutions in its Energy & Mitochondrial Series: Liposomal NMN formula (NMN + Resveratrol + TMG), Sublingual NR formula (NR + Resveratrol), and a comprehensive NAD+ pathway blend (NMN + PQQ + Ubiquinol CoQ0 + NADH + TMG). We support OEM/ODM customization across capsules, powders, and sublingual tablets. Our formulations follow a complete anti-aging logic centered on "NAD+ precursor supplementation +SIRT1 activation + methyl cycle support."
